全文获取类型
收费全文 | 130041篇 |
免费 | 11702篇 |
国内免费 | 5686篇 |
专业分类
耳鼻咽喉 | 531篇 |
儿科学 | 3254篇 |
妇产科学 | 1283篇 |
基础医学 | 24518篇 |
口腔科学 | 1452篇 |
临床医学 | 10388篇 |
内科学 | 32194篇 |
皮肤病学 | 1822篇 |
神经病学 | 4877篇 |
特种医学 | 2023篇 |
外国民族医学 | 14篇 |
外科学 | 7461篇 |
综合类 | 17860篇 |
现状与发展 | 31篇 |
预防医学 | 13632篇 |
眼科学 | 1322篇 |
药学 | 13214篇 |
31篇 | |
中国医学 | 5176篇 |
肿瘤学 | 6346篇 |
出版年
2024年 | 205篇 |
2023年 | 1552篇 |
2022年 | 3905篇 |
2021年 | 4778篇 |
2020年 | 4274篇 |
2019年 | 4473篇 |
2018年 | 4387篇 |
2017年 | 4409篇 |
2016年 | 4939篇 |
2015年 | 5400篇 |
2014年 | 8157篇 |
2013年 | 8713篇 |
2012年 | 8112篇 |
2011年 | 8925篇 |
2010年 | 7288篇 |
2009年 | 6692篇 |
2008年 | 6620篇 |
2007年 | 6569篇 |
2006年 | 6032篇 |
2005年 | 5233篇 |
2004年 | 4505篇 |
2003年 | 3973篇 |
2002年 | 3210篇 |
2001年 | 3002篇 |
2000年 | 2375篇 |
1999年 | 2090篇 |
1998年 | 1882篇 |
1997年 | 1676篇 |
1996年 | 1419篇 |
1995年 | 1422篇 |
1994年 | 1275篇 |
1993年 | 1037篇 |
1992年 | 886篇 |
1991年 | 710篇 |
1990年 | 636篇 |
1989年 | 570篇 |
1988年 | 523篇 |
1987年 | 409篇 |
1986年 | 345篇 |
1985年 | 772篇 |
1984年 | 676篇 |
1983年 | 524篇 |
1982年 | 521篇 |
1981年 | 437篇 |
1980年 | 388篇 |
1979年 | 337篇 |
1978年 | 282篇 |
1977年 | 213篇 |
1976年 | 216篇 |
1975年 | 165篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
51.
52.
53.
54.
《中国现代医生》2020,58(2):135-138+封三
目的探讨实时剪切波弹性成像在评估拉米夫定治疗乙肝纤维化临床疗效中的作用。方法选取2017年1月~2018年1月我院收治的80例乙肝纤维化患者,根据随机数字法分为对照组和观察组,每组40例。对照组采用常规治疗,观察组在对照组的基础上给予拉米夫定进行治疗,治疗6个月。比较两组治疗前后肝功能、肝纤维化指标,利用实时剪切波弹性成像评估两组治疗前后肝脏弹性模量值及肝穿刺活检情况,并进行比较。结果两组治疗后AST、ALT、TBIL水平均明显低于治疗前,差异有统计学意义(P0.05);观察组治疗后AST、ALT、TBIL水平均明显低于对照组,差异有统计学意义(P0.05);两组治疗后HA、LN、PⅢPN-P、CL-Ⅳ水平及杨氏弹性模量值均显著低于治疗前,差异有统计学意义(P0.05);观察组治疗后HA、LN、PⅢPN-P、CL-Ⅳ水平及杨氏弹性模量值均显著低于对照组,差异有统计学意义(P0.05);与治疗前相比,两组治疗后肝穿刺活检结果均有好转,尤其是汇管区、肝小叶内炎症及肝纤维化改善明显。结论实时剪切波弹性成像作为肝脏硬度定量检测的无创性技术,可用于拉米夫定治疗乙肝纤维化临床疗效评估的重要方法。 相似文献
55.
Auda A. Eltahla Fabio Luciani Peter A. White Andrew R. Lloyd Rowena A. Bull 《Viruses》2015,7(10):5206-5224
The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-α-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development. Direct acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens. 相似文献
56.
《Vaccine》2016,34(8):1115-1125
Chronic hepatitis C virus (HCV) infection represents a major health threat to global population. In India, approximately 15–20% of cases of chronic liver diseases are caused by HCV infection. Although, new drug treatments hold great promise for HCV eradication in infected individuals, the treatments are highly expensive. A vaccine for preventing or treating HCV infection would be of great value, particularly in developing countries. Several preclinical trials of virus-like particle (VLP) based vaccine strategies are in progress throughout the world. Previously, using baculovirus based system, we have reported the production of hepatitis C virus-like particles (HCV-LPs) encoding structural proteins for genotype 3a, which is prevalent in India. In the present study, we have generated HCV-LPs using adenovirus based system and tried different immunization strategies by using combinations of both kinds of HCV-LPs with other genotype 3a-based immunogens. HCV-LPs and peptides based ELISAs were used to evaluate antibody responses generated by these combinations. Cell-mediated immune responses were measured by using T-cell proliferation assay and intracellular cytokine staining. We observed that administration of recombinant adenoviruses expressing HCV structural proteins as final booster enhances both antibody as well as T-cell responses. Additionally, reduction of binding of VLP and JFH1 virus to human hepatocellular carcinoma cells demonstrated the presence of neutralizing antibodies in immunized sera. Taken together, our results suggest that the combined regimen of VLP followed by recombinant adenovirus could more effectively inhibit HCV infection, endorsing the novel vaccine strategy. 相似文献
57.
《Vaccine》2020,38(10):2315-2325
In the preparation of glycoconjugate vaccines in clinical practice, two highly immunogenic carrier proteins, CRM197 and tetanus toxoid (TT), are predominantly conjugated with the capsular polysaccharides (CPSs) of bacterial pathogens. In addition, TT has long been used as an effective vaccine to prevent tetanus. While these carrier proteins play an important role in immunogenicity and vaccine design alike, their defined human major histocompatibility complex class II (MHCII) T cell epitopes are inadequately characterized. In this current work, we use mass spectrometry to identify the peptides from these carrier proteins that are naturally processed and presented by human B cells via MHCII pathway. The MHCII-presented peptides are screened for their T cell stimulation using primary CD4+ T cells from four healthy adult donors. These combined methods reveal a subset of eleven CD4+ T cell epitopes that proliferate and stimulate human T cells with diverse MHCII allelic repertoire. Six of these peptides stand out as potential immunodominant epitopes by responding in three or more donors. Additionally, we provide evidence of these natural epitopes eliciting more significant T cell responses in donors than previously published TT peptides selected from T cell epitope screening. This study serves toward understanding carrier protein immune responses and thus enables the use of these peptides in developing novel knowledge-based vaccines to combat persisting problems in glycoconjugate vaccine design. 相似文献
58.
59.
《Molecular immunology》2015,63(2):296-304
Regulatory B cells (Bregs) are defined by their ability to restrain inflammatory responses both in vivo and in vitro. Interleukin 10 (IL-10) production by Bregs is thought to be central to their ability to regulate inflammation, largely due to IL-10s’ ability to suppress pro-inflammatory cytokine production by effector lymphocytes and to maintain the differentiation of regulatory T cells (Tregs). However, with an increase in available published data, it has become evident that Bregs utilize a number of suppressive mechanisms in order to alter the activation of a variety of different lymphocytes. Here, we summarize the multiplicity of cellular targets of Breg-mediated suppression and describe the mechanisms employed by Bregs to suppress chronic inflammatory responses. 相似文献
60.